diabetes.medicinematters.comMedicine Matters diabetes | An educational platform for healthcare professionals | diabetes.medicine

matters.com matters.com Menu Home Latest news Browse topics Chevron down icon Chevron up icon Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics EN EN In focus Chevron down icon Chevron up icon Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management Congress coverage Chevron down icon Chevron up icon EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific SessionsMedicine Matters Diabetes Medicine Matters Diabetes Search Search icon EXTENDED SEARCH Medicine Matters Diabetes JAVASCRIPT NEEDED Please enable JavaScript onYour version of Internet Explorer is no longer supported by this system. Please install one of the following browsers: Microsoft Edge, Safari, Chrome or Firefox Be confident that your patient care is up to date Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine’s complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account » Novel clinical evidence in continuous glucose monitoring Novel clinical evidence in continuous glucose monitoring How real-world studies complement randomized controlled trials Jean-Pierre Riveline uses data from real-life continuous glucose monitoring studies to illustrate how these can uncover critical information about clinical outcomes that are hard to assess in randomized controlled trials. This video has been developed through unrestricted educational funding from Abbott Diabetes Care. Watch the video NEWS | Diabetes devices & technology Automated insulin delivery benefits type 1 diabetes individuals at high hypoglycemia risk Pregnancy-specific closed-loop system proves feasible for home use Over 60s with type 1 diabetes show trust in Cambridge hybrid closed-loop system Flash glucose monitoring technology Browse slide sets summarizing results from real-world studies. View the full collection View the full collection » Real-world study: Determining the effectiveness of flash glucose monitoring on HbA1c in adults with type 2 diabetes » Clinical trial meta-analysis and real-world study: Impact of flash glucose monitoring on HbA1c » Funded by an educational grant from Abbott Diabetes Care IN FOCUS | Obesity & lifestyle interventions Doctor measures a man’s waist 07-03-2023 | Type 2 diabetes | News ‘Substantial’ bodyweight reductions with tirzepatide in people with type 2 diabetes and obesity SURMOUNT-2 trial results show bodyweight reductions with tirzepatide that rival those seen with other approved anti-obesity medications in people with type 2 diabetes. More on obesity & lifestyle interventions NEWS | Obesity & lifestyle interventions Prediabetes remission with lifestyle intervention reduces type 2 diabetes risk Gestational diabetes independently linked to increased future mortality risk Young-onset type 2 diabetes diagnosis linked to shortened life expectancy Semaglutide for weight loss: The STEP and SELECT trials Get the latest results and insights from the researchers. Browse the hub Browse the hub IN FOCUS | Hypoglycemia Data for health analytics concept 03-03-2023 | Healthcare systems | News Health informatics system aids timely, equitable diabetes care A health informatics system based on routine clinical data helps physicians to prioritize high-risk people with diabetes, deliver more equitable care, and manage healthcare capacity, report researchers. More on hypoglycemia NEWS | Hypoglycemia Automated insulin delivery benefits type 1 diabetes individuals at high hypoglycemia risk ONWARDS 5: Weekly insulin icodec with app shows real-world promise for type 2 diabetes ONWARDS 2: Weekly insulin icodec superior to degludec in type 2 diabetes Supporting people with diabetes during Ramadan Evidence overview and practical advice for fasting with type 1 or type 2 diabetes Browse the hub Browse the hub IN FOCUS | Cardiovascular disorders Human heart with ecg graph. 3d illustration 11-18-2022 | Dapagliflozin | News Dapagliflozin HFpEF benefits independent of glucose levels People who have heart failure with preserved ejection fraction benefit from dapagliflozin irrespective of whether they have normal or impaired glucose metabolism, shows further analysis of DELIVER. More on cardiovascular disorders NEWS | Cardiovascular disorders Gestational diabetes independently linked to increased future mortality risk Latent autoimmune diabetes carries mortality and CVD risks comparable to type 2 diabetes Pragmatic trial suggests best cardioprotective agents for type 2 diabetes IN FOCUS | Tirzepatide Doctor measures a man’s waist 07-03-2023 | Type 2 diabetes | News ‘Substantial’ bodyweight reductions with tirzepatide in people with type 2 diabetes and obesity SURMOUNT-2 trial results show bodyweight reductions with tirzepatide that rival those seen with other approved anti-obesity medications in people with type 2 diabetes. More on tirzepatide NEWS | Tirzepatide & type 2 diabetes ‘Substantial’ bodyweight reductions with tirzepatide in people with type 2 diabetes and obesity Triple agonist shows early promise for type 2 diabetes SURPASS J trials support tirzepatide use in Japanese people with type 2 diabetes The SURPASS trials Get the latest reporting, researcher interviews, and independent commentary on tirzepatide for type 2 diabetes. Browse the hub Browse the hub IN FOCUS | Mental health & psychosocial care Lori Berard 04-14-2022 | Hyperglycemia | View from the clinic | Article Managing hyperglycemia related to stress Lori Berard highlights the contribution of stress to poor glycemic control and considers how healthcare providers can account for this in their practice. More on psychosocial care NEWS | Mental health & psychosocial care Over 60s with type 1 diabetes show trust in Cambridge hybrid closed-loop system Real-world isCGM benefits shown for people with psychosocial diabetes issues Anxiety, depression linked to impaired hypoglycemia awareness Addressing suicide risk in diabetes Learn about rates and risk, underlying psychological factors, and practical actions to support patients. Visit the hub Visit the hub IN FOCUS | GLP-1 receptor agonists Syringe and pills 11-01-2022 | SGLT2 inhibitors | News Real-world adjunctive medication outcomes in type 1 diabetes revealed People with type 1 diabetes who take GLP-1 receptor agonists or SGLT2 inhibitors in clinical practice have outcomes that are mostly – but not all – in line with those in controlled trials, say researchers. More on GLP-1 receptor agonists NEWS | GLP-1 receptor agonists Pragmatic trial suggests best cardioprotective agents for type 2 diabetes Triple agonist shows promise for both glycemic and weight control Cagrilintide plus semaglutide shows dual benefit in type 2 diabetes GLP-1 receptor agonists Browse the latest news, clinical trial updates, and expert commentary. Visit the topic page Visit the topic page IN FOCUS | Pediatric type 2 diabetes Weekly pill container 04-04-2022 | Dapagliflozin | News Phase 3 trial supports dapagliflozin in young people with type 2 diabetes The first phase 3 trial of an SGLT2 inhibitor in children and young people with type 2 diabetes shows...